Human CTRP9/C1qTNF9 Antibody

Detection of CTRP9/C1qTNF9 by Western Blot Overexpression of CTRP9 leads to increased glucose uptake in the heart during high-fat diet (HFD) administration. (A) Representative images of cardiac PET scans of the indicated HFD-fed mice treated either with AAV Luc (control) or AAV CTRP9 (leading to myocardial CTRP9 overexpression). 18F-fluoro-deoxyglucose was used as a tracer. (B) Dynamic glucose uptake measured through PET scans as described in (A). (C) Immunoblot of cardiac protein lysate of mice treated as shown. GAPDH was used as a loading control. INS: insulin. Data are shown as mean ± standard error of the mean (SEM). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36766785), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of CTRP9/C1qTNF9 by Western Blot Cardiac overexpression of CTRP9 leads to peripheral insulin resistance during administration of a high-fat diet (HFD). (A) Scheme showing the experimental timeline. (B) Immunoblotting for CTRP9 from cardiac protein lysate of mice treated either with AAV Luc (control, LUC) or AAV CTRP9 (CT9, leading to myocardial CTRP9 overexpression). (C) Body weight measured at 4, 8 and 12 weeks in the indicated mice after start of feeding. (D) Fasted serum glucose levels. (E) Glucose tolerance test in the indicated mice after 12 weeks of HFD. (F) Serum insulin levels. (G) HOMA-Index of insulin resistance. Data are shown as mean ± standard error of the mean (SEM). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36766785), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of CTRP9/C1qTNF9 by Western Blot Overexpression of CTRP9 leads to increased glucose uptake in the heart during high-fat diet (HFD) administration. (A) Representative images of cardiac PET scans of the indicated HFD-fed mice treated either with AAV Luc (control) or AAV CTRP9 (leading to myocardial CTRP9 overexpression). 18F-fluoro-deoxyglucose was used as a tracer. (B) Dynamic glucose uptake measured through PET scans as described in (A). (C) Immunoblot of cardiac protein lysate of mice treated as shown. GAPDH was used as a loading control. INS: insulin. Data are shown as mean ± standard error of the mean (SEM). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36766785), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of CTRP9/C1qTNF9 by Western Blot Cardiac overexpression of CTRP9 leads to peripheral insulin resistance during administration of a high-fat diet (HFD). (A) Scheme showing the experimental timeline. (B) Immunoblotting for CTRP9 from cardiac protein lysate of mice treated either with AAV Luc (control, LUC) or AAV CTRP9 (CT9, leading to myocardial CTRP9 overexpression). (C) Body weight measured at 4, 8 and 12 weeks in the indicated mice after start of feeding. (D) Fasted serum glucose levels. (E) Glucose tolerance test in the indicated mice after 12 weeks of HFD. (F) Serum insulin levels. (G) HOMA-Index of insulin resistance. Data are shown as mean ± standard error of the mean (SEM). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36766785), licensed under a CC-BY license. Not internally tested by R&D Systems.